Literature DB >> 1969512

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

I G McFarlane1, H M Smith, P J Johnson, G P Bray, D Vergani, R Williams.   

Abstract

An enzyme immunoassay (Ortho-HCV ELISA) for antibodies against the hepatitis C virus (HCV) was used to test 143 serum samples from 53 patients with autoimmune chronic active hepatitis (AI-CAH). Optical density (OD) values in the assay correlated closely with serum globulin (r = 0.8846, p much less than 0.0005) and IgG (r = 0.6281, p less than 0.0005) concentrations but not with immunosuppressant therapy. OD values were positive in 20 (65%) of 31 with active disease and in only 1 (5%) of 22 in remission (p less than 0.0005). The association between positive results and active disease and high serum globulin levels was confirmed by serial studies in 6 of the patients. In contrast, none of 31 patients with primary biliary cirrhosis and only 2 of 24 with non-hepatic disorders associated with high IgG concentrations were positive, and these controls showed no correlation between OD values and serum globulins or IgG. The findings suggest that serum from AI-CAH patients may contain a component that gives false-positive results in the assay.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969512     DOI: 10.1016/0140-6736(90)90870-b

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  71 in total

1.  Hepatitis C testing. Comparison of Ortho's EIA and RIBA II tests in 1,182 patients undergoing primary liver transplantation.

Authors:  M Rochlani; J H Lewis; G E Ramsey; F A Bontempo; G Shah; R A Bowman; D H van Thiel; T E Starzl
Journal:  Am J Clin Pathol       Date:  1992-07       Impact factor: 2.493

Review 2.  Immunological abnormalities and hepatotropic viral infections.

Authors:  I G McFarlane
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

3.  Prevalence of antibody to hepatitis C virus in an isolated Canadian Inuit settlement.

Authors:  G Minuk; L Nicolle; T Gauthier; J Brunka
Journal:  Can J Infect Dis       Date:  1991

Review 4.  Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy.

Authors:  M R Jacyna; H C Thomas
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

Review 5.  Sexually transmitted hepatitis: a review.

Authors:  R J Gilson
Journal:  Genitourin Med       Date:  1992-04

6.  Serological prevalence of hepatitis C virus in a population of subjects with human immunodeficiency virus infection.

Authors:  A Lafeuillade; C Zandotti; C Tamalet; R Quilichini; J A Gastaut
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 7.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

8.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

9.  Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis.

Authors:  J M Pawlotsky; L Deforges; S Bretagne; C André; J M Métreau; V Thiers; E S Zafrani; M Goossens; J Duval; J P Mavier
Journal:  Gut       Date:  1993       Impact factor: 23.059

10.  Role of hepatitis C virus in chronic liver disease occurring after orthotopic liver transplantation.

Authors:  M Pastore; M Willems; C Cornu; J P Buts; R Reding; J de Ville de Goyet; J Rahier; J B Otte; S H Yap; E M Sokal
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.